It has completed the acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals.
7 months ago

Press release - Coherent Market Insights Pvt. Ltd - Anal Cancer Market to Witness Massive Growth by 2032 | Advaxis, Inc., ORYX GmbH and Co.
2 weeks ago

OS Therapies has penned a deal that will secure the full intellectual property rights to the drug along with a pair of additional clinical-stage therapies.
9 months ago

(OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology...
33 months ago

NEW YORK - OS Therapies (NYSE-A: OSTX), a biopharmaceutical company specializing in immunotherapy and Antibody Drug Conjugates (ADC),...
7 months ago

OS Therapies Inc. struck an $8 million deal to take back ownership of the cancer treatment candidates it's been licensing from another drug company.
9 months ago

The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight's lead product,...
52 months ago

Advaxis enters merger deal with biotech firm Ayala. Stockholders of Ayala and Advaxis will own nearly 62.5% and 37.5% of the outstanding common...
36 months ago

Morgan Lewis is representing Advaxis Inc. in its entry into a definitive merger agreement with Ayala Pharmaceuticals Inc.
36 months ago

Princeton-based Advaxis Inc., a biotechnology company focused on immunotherapy products, announced Monday leadership changes to its...
90 months ago